• Image 01
  • Image 02
  • Image 03
  • Image 04
  • Image 05
  • Image 06
Need assistance? Contact Us: 1-800-255-5897

Menu

  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Tevogen Bio Holdings Inc. - Common Stock (NQ:TVGN)

0.3179 +0.0041 (+1.31%)
Streaming Delayed Price Updated: 4:00 PM EST, Jan 14, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 515,171
Open 0.3300
Bid (Size) 0.3151 (1,000)
Ask (Size) 0.3310 (500)
Prev. Close 0.3138
Today's Range 0.3054 - 0.3300
52wk Range 0.2990 - 1.920
Shares Outstanding N/A
Dividend Yield N/A
Chart for  (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
News headline image
FDA Reversal Sends Atara Biotherapeutics into Tailspin: Stock Plummets 67% on Second CRL for Tabelecleucel
January 14, 2026
In a stunning blow to the burgeoning field of allogeneic cell therapy, Atara Biotherapeutics (Nasdaq: ATRA) saw its market valuation evaporate this week following a second Complete Response Letter... 
Via MarketMinute
Topics Bankruptcy
News headline image
Tevogen Demonstrates Platform Scalability and Multi-Indication T Cell Pipeline Expansion in 2025
January 12, 2026
From Tevogen Bio Inc
Via GlobeNewswire

Performance

YTD
-12.6%
-12.6%
1 Month
-20.2%
-20.2%
3 Month
-57.9%
-57.9%
6 Month
-74.2%
-74.2%
1 Year
-74.4%
-74.4%

More News

Read More
News headline image
Tevogen CEO Donates Shares to Support Education for Underprivileged Children
December 22, 2025
From Tevogen Bio Inc
Via GlobeNewswire
News headline image
Tevogen CEO Donates Personal Shares to Support Local Fire Department
December 19, 2025
From Tevogen Bio Inc
Via GlobeNewswire
News headline image
Tevogen CEO Supports Local Law Enforcement with Personal Contribution of 230,000 Company’s Shares of Common Stock
December 11, 2025
From Tevogen Bio Inc
Via GlobeNewswire
News headline image
Tevogen Celebrates Board Member Dr. Curtis Patton, Honored by Yale University for Distinguished Career and Lasting Contributions to Medical Education and Equity in Medicine
December 09, 2025
From Tevogen Bio Inc
Via GlobeNewswire
News headline image
Tevogen Highlights Continued Capital Efficiency Following Filing of Q3 2025 Form 10-Q
November 14, 2025
From Tevogen Bio Inc
Via GlobeNewswire
News headline image
Tevogen Reports Major Clinical Milestone: Expands HLA Coverage of its Investigational Precision T Cell Therapy for Acute and Long COVID
November 05, 2025
From Tevogen Bio Inc
Via GlobeNewswire
News headline image
Tevogen Clarifies Reported Financials, Highlighting Strong Capital Efficiency and Low Cash Burn
November 03, 2025
From Tevogen Bio Inc
Via GlobeNewswire
News headline image
Tevogen Senior Management Engages with Business and Community Leaders and Highlights Recent Progress
October 29, 2025
From Tevogen Bio Inc
Via GlobeNewswire
News headline image
Tevogen Updates on TVGN 489 Following Growing Long COVID Patient Interest
October 15, 2025
From Tevogen Bio Inc
Via GlobeNewswire
News headline image
Tevogen Marks Major Milestone in Its AI Initiative to Enhance Efficacy of T Cell–Based Therapies with 100x PredicTcell™ Beta Data Expansion
September 25, 2025
From Tevogen Bio Inc
Via GlobeNewswire
News headline image
Tevogen Highlights Potential Role of TVGN 489 in Eliminating Persistent Viral Reservoirs Linked to Long COVID
September 23, 2025
From Tevogen Bio Inc
Via GlobeNewswire
News headline image
Tevogen Commends HHS for Addressing Long COVID, Emphasizes TVGN 489’s Potential Impact for 20 Million Americans
September 19, 2025
From Tevogen Bio Inc
Via GlobeNewswire
News headline image
Tevogen CIO and Head of Tevogen.AI Mittul Mehta to Join Startup Forum Panel at Databricks DATA + AI World Tour in Boston
September 10, 2025
From Tevogen Bio Inc
Via GlobeNewswire
News headline image
Tevogen Estimates 5-Year Top-Line Revenue of ∼$6.5 Billion For Product Focused on Liver Cancer Prevention with High-Risk Chronic Hepatitis B Infection
September 09, 2025
From Tevogen Bio Inc
Via GlobeNewswire
News headline image
Tevogen Values TVGN-489 at $9–$11 Billion rNPV, Its First Clinical Product From the Proprietary ExacTcell™ Allogeneic T Cell Platform
September 08, 2025
From Tevogen Bio Inc
Via GlobeNewswire
News headline image
Tevogen Shares Valuation of Key Assets and Potential Forecast For Pipeline Product Focused on EBV Associated Leukemia and Lymphomas
September 04, 2025
From Tevogen Bio Inc
Via GlobeNewswire
News headline image
Tevogen Underscores the Importance of Precision Immunotherapies, Including TVGN 489 for Vulnerable Individuals Infected with SARS-CoV-2
September 03, 2025
From Tevogen Bio Inc
Via GlobeNewswire
News headline image
Tevogen Bio Highlights Proprietary Assets and Upcoming Valuation Disclosure
August 27, 2025
From Tevogen Bio Inc
Via GlobeNewswire
News headline image
Tevogen Expresses Gratitude to Yale for Recognition of Dr. Ryan Saadi and Company’s Mission of Health Equity
August 26, 2025
From Tevogen Bio Inc
Via GlobeNewswire
News headline image
Tevogen Sees Continued Growth in Institutional Ownership in Q2 2025; 72% of Holders Increased or Maintained Positions
August 25, 2025
From Tevogen Bio Inc
Via GlobeNewswire
News headline image
Tevogen Recognized in BINJE’s BEST Health Care 2025 for Advancing Health Equity and Sustainable Biopharma
August 22, 2025
From Tevogen Bio Inc
Via GlobeNewswire
News headline image
REPEAT -- Tevogen Bio Enters Into Agreement for Up to $50 Million in Financing to Advance R&D and Clinical Development Efforts
August 19, 2025
From Tevogen Bio Inc
Via GlobeNewswire
News headline image
Tevogen Delivers Stronger Second Quarter and First Half 2025 Financial Results with Reduced Expenses and Growth Momentum
August 19, 2025
From Tevogen Bio Inc
Via GlobeNewswire

Frequently Asked Questions

Is Tevogen Bio Holdings Inc. - Common Stock publicly traded?
Yes, Tevogen Bio Holdings Inc. - Common Stock is publicly traded.
What exchange does Tevogen Bio Holdings Inc. - Common Stock trade on?
Tevogen Bio Holdings Inc. - Common Stock trades on the Nasdaq Stock Market
What is the ticker symbol for Tevogen Bio Holdings Inc. - Common Stock?
The ticker symbol for Tevogen Bio Holdings Inc. - Common Stock is TVGN on the Nasdaq Stock Market
What is the current price of Tevogen Bio Holdings Inc. - Common Stock?
The current price of Tevogen Bio Holdings Inc. - Common Stock is 0.3179
When was Tevogen Bio Holdings Inc. - Common Stock last traded?
The last trade of Tevogen Bio Holdings Inc. - Common Stock was at 01/14/26 04:00 PM ET
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

Having difficulty making your payments? We're here to help! Call 1-800-255-5897

Copyright © 2019 Franklin Credit Management Corporation
All Rights Reserved
Contact Us | Privacy Policy | Terms of Use | Sitemap